The PD-1 resistant head and neck cancer market — treatments for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who progress despite standard PD-1 checkpoint inhibitor therapy — is emerging as one of oncology's more urgent unmet-need categories, with the PD-1 Resistant Head and Neck Cancer Market reflected across analyst estimates that vary by...